



Universiteit
Leiden
The Netherlands

Challenges and opportunities in nasal subunit vaccine delivery : mechanistic studies using ovalbumin as a model antigen

Slütter, B.A.

Citation

Slütter, B. A. (2011, January 27). *Challenges and opportunities in nasal subunit vaccine delivery : mechanistic studies using ovalbumin as a model antigen*. Retrieved from <https://hdl.handle.net/1887/16394>

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/16394>

Note: To cite this publication please use the final published version (if applicable).

2

Rational design of nasal vaccines

Bram Slütter

Niels Hagenars

Wim Jiskoot

Journal of Drug Targeting 2008 16(1):1-17

Abstract

Nasal vaccination is a promising alternative to classical parental vaccination, as it is non-invasive and, in principle, capable of eliciting strong systemic and local immune responses. However, the protective efficacy of nasally administered antigens is often impaired because of delivery problems: free antigens are readily cleared from the nasal cavity, poorly absorbed by nasal epithelial cells and generally have low intrinsic immunogenicity. In this review paper, we describe the main physiological hurdles to nasal vaccine delivery, survey the progress made in technological approaches to overcome these hurdles and discuss emerging opportunities for improving nasal vaccines. According to current insights, encapsulation of the antigen into bioadhesive (nano)particles is a promising approach towards successful nasal vaccine delivery. These antigen-loaded particles can be tailor made by supplying them with targeting ligands, adjuvants or endosomal escape mediators to form the desired vaccine that provides long-lasting protective immunity.

Introduction

Vaccination is the most cost effective way of fighting infectious diseases. Although some vaccination strategies have been very successful, novel approaches are needed to develop safe and effective vaccines against diseases like HIV/AIDS, malaria, influenza and cancer. Additionally, adverse reactions, like pain, fever, headaches, nausea and allergic reactions have led to declined patient compliance [1-6] and have prompted governments and health organizations to enlarge their funds for research and development of non-invasive vaccines [7-9]. Among the potential needle free routes, nasal vaccination is particularly attractive. The nasal cavity had been the preferred delivery site until the introduction of the hollow needle in the 19th century [10]. In the search for alternatives to the needle, the interest in nasal vaccination has reemerged. This paper will review the main physiological hurdles that have to be overcome to render nasal vaccination successful, describe the progress made in the field of nasal delivery of subunit vaccines, and discuss emerging opportunities for improving nasal vaccines.

Nasal vaccination

Nasal vaccination has several interesting advantages. The nose is easily accessible and the nasal cavity is equipped with a high density of dendritic cells (DC) that can mediate strong systemic and local immune responses against pathogens that invade the human body through the respiratory tract [11-13]. Mucosal immunity is mediated by secretory immunoglobulin A (sIgA) antibodies, which prevent pathogens from colonizing mucosal epithelia (e.g. respiratory tract, gastro intestinal tract) and hence clear the organisms before they invade the underlying tissue.

Local immunity in the upper airways, as well as systemic immunity, is mainly mediated by the lymphoid tissue referred to as nasal associated lymphoid tissue (NALT). NALT is comprised of agglomerates of cells involved in the initiation and execution of an immune response, like DC, T-cells and B-cells [14], situated underneath the nasal epithelium. NALT is most pronounced in the nasopharynx and the Waldeyer's ring, which includes the nasopharyngeal, tubal, palatine and lingual tonsils, making the adenoids an important part of the NALT. Indeed some studies have shown that sIgA excretion is dependent on these areas and tonsillectomy has been associated with decreased immunity [15, 16]. Moreover, Zuercher *et al* [17] showed the presence of germinal centers (places where plasma cells are located) in the NALT after

challenge with a reovirus, and Shimoda *et al* [18] showed that B-cells in the subepithelial region of the nose are prone to switch from IgM to IgA, indicating a role for the NALT as inductive site for immune responses. Mucosal immunity after nasal vaccination is, however, not restricted to the upper airways. Via a system called the common mucosal immune system, after nasal immunization sIgA antibodies also can be detected also in other mucosal secretions.

In spite of the large effort that has been directed to developing nasal vaccines, only one nasal vaccine is currently on the market (Table I). Furthermore, nasal vaccine delivery may be compromised in patients with respiratory infections and the need for an effective delivery device should not be overlooked. In attempts made to improve the immunogenicity of nasal subunit vaccines, the vaccine formulation plays a crucial role, as will be further discussed below.

*Table I. Examples of nasal vaccines currently on the market or at different stages of development.**

Immunization route	Disease	Pathogen	Vaccine type	Phase
Nasal	Influenza	<i>Influenza virus</i>	Live attenuated	On market
	Hepatitis B	<i>Hepatitis B virus</i>	Subunit vaccine	Phase I
	Influenza	<i>Parainfluenza virus type 3</i>	Live attenuated	Preclinical
	Anthrax	<i>Bacillus anthracis</i>	Killed/inactivated	Preclinical
	Herpes	<i>Herpes simplex virus</i>	Killed/inactivated	Preclinical
	Bronchiolitis/ Pneumonia	<i>Respiratory syncytial virus</i>	Killed/inactivated	Preclinical
	Cervical cancer	<i>Human papillomavirus</i>	Subunit vaccine	Preclinical
	SARS	<i>SARS corona virus</i>	Subunit vaccine	Preclinical

*Based on [19] and [20]

Roadmap to successful nasal vaccine delivery

After nasal administration of a vaccine, a number of successive steps should lead to a protective immune response (Fig. 1). In this section we will describe these steps and discuss how a vaccine delivery system can enhance the immune response by promoting these steps.

Prolonging the nasal residence time

After intranasal (i.n.) administration, the first step in the trajectory towards an immune response is that the antigen reaches the NALT. In principle, there is no direct contact between DC in the subepithelial regions of the nose and the antigen in the lumen, although it has been suggested that DC can partially penetrate the epithelium making them capable of sampling the mucosal surface [21]. Therefore, during the limited nasal residence time of the vaccine, the antigen must cross the nasal epithelium. Increasing the residence time of the vaccine (normally ca. 20 minutes), with use of mucoadhesive substances, may therefore be a possible approach to improve the efficacy of a vaccine (Fig. 1).

M-cell targeting

The mechanism of antigen uptake through the epithelium is somewhat controversial. The epithelium is composed of only a thin layer of pseudostratified epithelial cells, connected by tight junctions. Since the diameter of tight junctions is only a few Ångströms [22], it is very unlikely that (killed) bacteria or viruses, bulky antigens, or particulate vaccine delivery systems are able to penetrate this barrier by paracellular transport even if the tight junctions are widened up [23]. Transcellular transport is a more likely route by which (particulate) antigens reach the NALT. In particular, microfold cells (M-cells) serve as a portal for particulate antigens to enter the subepithelial region [12, 24-26]. M-cells are part of the NALT and cover the subepithelial dome containing DC, B-cells and T-cells. M-cells do not contain cilia and have relatively high concentrations of cytoskeleton protein vimentin [27, 28], making M-cells easily accessible and flexible, respectively, to be involved in transmembranous transport [29]. Indeed, after recognition and internalization, M-cells can transport particulate antigens to the NALT, by transcytosis [30]. Unlike epithelial cells, M-cells have been reported to efficiently take up antigens with a particulate nature and deliver them to a lymphatic environment rather than to the systemic circulation. This may explain why the increased efficiency of particulate antigens is undisputed, whereas increased drug transport using particles is still under discussion [31]. Hence, improving the uptake of a vaccine through M-cells would target the antigen to the underlying immune cells, and may thereby contribute to higher immune responses (Fig. 1).

DC signaling

After antigen uptake, DC mature and migrate to the nearby cervical lymph nodes, where they present the peptides on MHC class 2 (MHC II) molecules to helper T (Th) cells. Upon recognition of the MHC II-peptide complex and costimulation from APC, naïve Th cells

differentiate into effector Th cells, which can be divided in two major subtypes: Th1 and Th2 cells. Th1 cells are mainly involved in activation and proliferation of the cellular immune system, whereas Th2 cells are involved in stimulation and increase of the humoral immune responses. The DC signaling determines the fate of the naïve Th cell and can be influenced by the use of delivery systems and adjuvants. So, not only can delivery systems and adjuvants increase immune responses, they can also influence the Th1/Th2 balance, i.e. the type of immune response. Since the optimal balance of the immune reaction is dependent on the pathogen in question, induction of the desired type of immune response should be tailored for each specific vaccine, which can be achieved by the use of proper delivery systems and adjuvants.





Figure 1:
Schematic overview of the consecutive steps towards successful nasal vaccine delivery: 1) mucoadhesion; 2) antigen uptake, by M-cell transport; 3) delivery to and subsequent activation/maturation of DC; 4) induction of B-cell and T-cell responses. DC = dendritic cell, M-cell = microfold cell, Th cell = helper T cell.

Induction of CTL immune responses.

Obtaining immunity against intracellular pathogens like intracellular bacteria and viruses often requires the induction of CTL responses. The induction of CTL with a vaccine can only be achieved when a number of requirements are fulfilled. Firstly, the vaccine should contain class I (MHC I) epitopes. Secondly, an MHC II epitope must be present in the vaccine, since a strong induction of CTL responses is only possible when Th cells are co-activated. Thirdly, the MHC I epitope should enter the MHC I presentation pathway.



DC copulsed with a Th1 and a Th2 inducing antigen were shown to direct these antigens to distinct compartments, leading to different, antigen dependent polarization of the immune response [32]. Presentation of exogenous antigens by MHC I molecules is called cross presentation [33, 34]. Recently, it was described that the mechanism of antigen uptake, which dictates the intracellular destination compartment, is not only involved in the activation and polarization of Th cells, but also determines whether the antigen is presented to either CD4⁺ Th cells or CD8⁺ CTL. This would suggest that a DC itself is not polarized upon ingestion of an antigen; rather, each intracellular compartment can prepare different instructions that can be presented to different T cells by one DC [35, 36]. Targeting mediators in the vaccine formulation could be employed to facilitate the delivery of endocytosed antigens to the desired intracellular compartments and thereby promote cross presentation (Figure 2).

Adjuvant targets. Adjuvants can be classified according to their mechanisms of action. One group of adjuvants acts through binding to pathogen recognition receptors (PRR) on cells. The binding of PAMP to PRR activates an intracellular signaling cascade in the innate immune cells, which eventually leads to DC maturation, cytokine production and costimulatory signaling to Th cells (Fig. 2).

The Toll-like receptor (TLR) family is a group of PRR that has been characterized in detail [37]. TLR are expressed by DC and recognize PAMP (Fig. 2) like lipopolysaccharide (LPS), dsRNA, CpG motifs and bacterial lipoproteins [38, 39]. Simultaneous stimulation of these innate immune receptors and antigen delivery to the DC generally leads to Th1 responses and Th1 dependent antibody isotypes [37], but some TLR ligands induce Th2 cytokines upon activation of the TLR [40]).

Another group of adjuvants are toxin based adjuvants. Enterotoxins like the cholera toxin (CT) and the *Escherichia coli* heat labile toxin (LT) are strong mucosal adjuvants that induce mucosal as well as serum antibody responses [41, 42]. LT and CT consist of a toxic A subunit with ADP-ribosyltransferase activity, which is linked non-covalently to a pentamer of B subunits that bind to ganglioside GM-1 receptors found on most cells [43]. Since the use of LT has been associated with neurological toxicity, efforts have been made to develop non-toxic mutants of LT and CT. The exact mechanism of adjuvanticity of toxin-based adjuvants is not fully understood, but the toxins CT and LT induce expression of B7 molecules on DC that can subsequently deliver costimulatory signals to Th cells (Fig. 2) [44].

Cytokines are probably the critical communication molecules of most classical adjuvants [45]. Therefore cytokines and other costimulatory molecules have been evaluated

as adjuvants to promote T-cell activation (Fig. 2). Similarly, antibodies mimicking the binding of these molecules to receptors on the T-cells have been tested as adjuvants.

Approaches to improve nasal vaccine delivery

In this section we discuss, based on the roadmap described in the previous section, several approaches that have been described in the literature to improve the delivery and immunogenicity of nasally administered antigens.

Mucoadhesives

Subunit antigens, having little affinity for the nasal epithelium, are generally cleared within minutes. Prolonging the residence time is commonly accomplished by coadministering the antigen with mucoadhesives, usually polymers. The term mucoadhesive does not discriminate between the interaction with either the mucosal cell surface or the mucus covering this surface. If the adhesive also interacts with the antigen, both interactions can lead to a decreased mucociliary clearance of antigens.

Recently, Smart gave an overview of the basics and mechanisms of mucoadhesion [46]. Briefly, properties like hydrophilicity, crosslinking, charge, molecular weight and the presence of acidic or alkaline functional groups influence the mucoadhesion of a polymer. Mucoadhesive polymers can be divided in 3 categories according to their mechanism of interaction. The first category includes hydrophilic polymers that adsorb to the mucus by forming hydrogen bonds, like sodium alginate, sodium carboxymethylcellulose, hydroxypropyl methylcellulose and carbopol. The second class comprises cationic polymers, like chitosan-derived polymers interacting with the negatively charged mucin mainly by ionic interactions, although hydrogen bonds could also play a role [47, 48]. Additionally, chitosan derivatives can open tight junctions and thereby can increase the permeability of the epithelium [49], but its significance for improved antigen delivery is questionable. The third class of mucoadhesives involves thiolated polymers, thiomers, that can form covalent disulfide bonds with the cysteine groups in mucin [50]. Recent studies show that thiomers are the strongest mucoadhesives [51].

Antigens coadministered with mucoadhesive polymers, like hyaluronic acid [52], chitosan [53] and carboxymethylcellulose [54] have indeed shown increased antibody responses as compared to application of the antigen without any additives. However, serum antibody levels

reached by coadministration of *Bordetella pertussis* hemagglutinin vaccine [55], diphtheria toxoid [56], tetanus toxoid [57], anthrax protective protein [57], inactivated influenza virus [58] or herpesvirus 1 glycoprotein [59] with chitosan never exceeded levels reached by intramuscular (i.m.) injection, despite the capability of chitosan to increase the nasal residence time [60]. Clearly, a prolonged residence time is not the sole determinant for a successful vaccine.

Particulate antigen carriers

Uptake of antigens through the nasal epithelium can be increased by incorporation into particles [61]. For instance, i.n. administration in mice of antigens incorporated in nanoparticles composed of poly lactide-co-glycolide (PLGA), a biodegradable polymer, led to over 100 fold increased antibody responses in comparison with aqueous solution of parainfluenza virus proteins [62], hepatitis B soluble antigen [63], *Bordetella bronchiseptica* dermonecrotxin [64] and recombinant HIV proteins [65]. Polystyrene beads loaded with hemagglutinin led to increased protection against influenza in mice [66], probably due to enhanced antigen uptake [67]. Nasal application of liposomes loaded with killed measles virus [68], formaldehyde-killed *Yersinia pestis* [69], or influenza A hemagglutinin [70] even elicited superior IgG antibody levels than i.m. administered alum adsorbed antigen.

Mucoadhesive particles. Particles composed of mucoadhesive polymers are even more effective antigen carriers, as they combine prolonged residence time in the nasal cavity with the beneficial properties of particulate systems. Chitosan particles are well-known mucoadhesive antigen carriers. Coadministration of soluble chitosan with cholera toxoid or ovalbumin (OVA) induced higher immune responses than administration of antigen alone, but incorporation of the CT or OVA antigen into chitosan nanoparticles resulted in superior serum antibody levels in rats [71]. Similarly, Amidi *et al* showed that nasally applied influenza antigens incorporated in trimethylated chitosan (TMC) nanoparticles elicited superior IgG and sIgA antibody response as compared to naked antigen or antigen coadministered with TMC [72].

Alternatively, particulate antigen carriers can be rendered mucoadhesive by coating them with mucoadhesive polymers. Intranasal vaccination with hepatitis B surface antigen (HBsAg) encapsulated in chitosan coated PLGA particles resulted in a 30 fold increase of serum IgG levels in comparison with uncoated HBsAg loaded PLGA particles [73]. Vila *et al* showed that chitosan coating of tetanus toxoid-containing PLA particles increases transport through the nasal epithelium in comparison with uncoated particles [74]. The increased transport was

accompanied by higher IgG responses against tetanus toxoid, indicating a positive effect of epithelial transport on vaccine efficacy.

Particle characteristics. The physicochemical properties of the particles most likely are critical to the effectiveness of the vaccine. For instance, particle size and zeta potential can impact the transport by M-cells as well as subsequent events, but the ideal particle characteristics are still under discussion.

The effect of particle size has not been thoroughly investigated for nasal vaccination. It has been determined that M-cells in Peyer's patches in the gut selectively take up particles with a diameter up to 10 μm [75] and that the particle size influences the type of immune response [76]. Xiang *et al* stated that particles resembling the size of viruses (20-200 nm) will be handled by the immune system as being a virus and elicit a cellular biased response, whereas particles with the size of a bacterium (between 0.5-5 μm) will favor a humoral response [77]. For nasal vaccination, several studies pointed to small (nano)particles being more rapidly absorbed by nasal M-cells [61, 71, 78-80], but no boundaries have been determined. Fujimura *et al* [81] showed that particles coated with the cationic polymers chitosan or poly-L-lysine were taken up by the NALT in a size range from 0.2 μm to 2 μm , with an increased uptake of smaller particles. Unfortunately, these particles did not carry an antigen, making it impossible to determine the effect of increased uptake on resulting immune responses.

As the cell membrane of M-cells is negatively charged, one can argue that a positive zeta potential is beneficial for M-cell transport. However, mucus and epithelial cells carry a negative charge as well, making electrostatic interactions very unspecific. Still, nasal application of a *Yersinia pestis* antigen in positively charged liposomes induced significantly stronger antibody responses than the same antigen in negatively charged liposomes [70, 82]. Likewise, nasal administration of HBsAg in positively charged PLGA microparticles resulted in significantly higher antibody levels than the same antigen in negatively charged PLGA microparticles (Jaganathan *et al* 2006). Although negatively charged or neutral particles have been reported to drastically increase antibody response after nasal immunisation [78, 83], positively charged particles seem to be superior to their negatively charged counterparts.

Improved mechanistic insight into the role of particle characteristics on antigen uptake will be necessary to resolve the ideal characteristics of a particulate carrier for uptake by the nasal epithelium.

M-cell targeting approaches

Specific M-cell targeting could further enhance vaccine efficacy. A variety of microorganisms, e.g. influenza viruses and group A streptococci, have been found to target

themselves to M-cells [12, 24, 25]. Complete bacteria can be used as vaccine carrier, exploiting their M-cell targeting mechanisms. Expression of *Streptococcus pneumoniae* antigens on live lactobacillus led to high IgG and sIgA titers in mice after i.n. administration [84]. Since live and inactivated lactobacilli induced similar protective immunity after nasal administration [85], the positive effect of lactobacillus is likely not due to prolonged residence time, but rather to increased bioadhesion or (M-cell mediated) uptake.

Virosomes are reconstituted virus envelopes, including a lipid bilayer and surface proteins. For instance, influenza virosomes (containing hemagglutinin and neuraminidase surface antigen) can be used as carriers to transport antigens to the cytosol of cells that overexpress sialic acid residues [86, 87] and might be exploited to target DC [88], but could target M-cells by the same mechanism. Virosomes have been shown to be excellent nasal carriers for several antigens like the F-protein of RSV [89] and DNA vaccines [90].

M-cells express several adhesion molecules on their cell surface that can bind pathogens. However, most work has been done on intestinal M-cells [91-93] and regional differences between M-cells exist [94, 95]. For instance, the plant lectin *Ulex europaeus* 1 lectin (UEA-1) [96] as well as lectins from other species [97-99] have been successfully used for targeting particles to intestinal M-cells in mice, but the specificity of UEA-1 for nasal M-cells is lower, as it also has affinity for nasal epithelial and goblet cells [100]. Despite this shortcoming, UEA-1 has been shown to increase M-cell transport and able to raise serum antibody levels when coadministered i.n. with DNA encoding HIV envelope protein [101].

Putative ligands that selectively target nasal M-cells include isolectin B₄ and *Maackia amurensis* I lectin [100], which recognize α -(1-3)-linked galactose and sialic acid, respectively [102]. Interestingly, sialic acid and galactose residues are involved in the initial binding of influenza virion to the host cell [103] and influenza A type viruses adhere efficiently to nasal M-cells *in vitro* [24]. Adherence of *Streptococcus pneumoniae* to the tracheal epithelium in chinchillas is dependent on the expression of sialic acid [104], showing the importance of these carbohydrate residues on the nasal epithelium for the entrance of these airborne pathogens. Nasal application of the model antigen HRP with isolectin B₄ significantly enhanced the antibody (IgG and sIgA) response to HRP in comparison with administration of HRP alone [102]. Recently it has been established that the Fc part of sIgA (and IgG alike) may also target M-cell, thereby creating a positive feedback loop [105]. Consequently coating particles with sIgA or IgG can increase M-cell transport [106] and have been shown to increase the immunogenicity of liposomal HBsAg formulation after nasal administration [107].

Finally, several other receptors have recently been identified as potential M-cell targeting ligands, especially β_1 -integrin [108]. Several pathogens use β_1 -integrins to cross the intestinal

epithelium, such as *Yersinia pestis* [109] and *Escherichia coli* [110, 111]. Recently Gullberg *et al* showed that uptake of latex particles by human intestinal M-cells *in vitro* was increased when the particles were coated with a β_1 -integrin ligand [112]. Hicks *et al* [113] showed that β_1 -integrin is also readily expressed on nasal isolectin B₄ positive epithelial cells, i.e. most probably M-cells.

Intracellular targeting, induction of cytotoxic T cells

After antigen uptake through the nasal epithelium, their uptake and processing by DC are the next critical steps that determine the immune response. Antigen delivery systems that are capable of disrupting the DC's endosomal membrane and thereby promote endosomal escape can in principle be used to induce CTL responses. It has been shown that antigens incorporated in particulate antigen delivery systems are more effectively cross-presented than soluble antigens [114-116]. The efficiency of cross-presentation can vary between different types of particulate antigen delivery systems.

ISCOMs and ISCOMATRIX adjuvant are 40-nm cage-like structures composed of Quillaja saponins, cholesterol, and lipids that can incorporate or associate membrane antigens and DNA. ISCOMs are well-studied nasal and parenteral adjuvants that induce not only mucosal and systemic humoral responses, but also CTL responses [117-121]. It is thought that ISCOMs can deliver antigens to the APC's cytosol due to their membrane-disrupting properties [120], triggering endosomal escape. Additionally, it has been shown that CTL induction is markedly stronger when the antigen is physically attached to the ISCOMATRIX rather than administered unbound [118].

Virosomes can also induce strong CTL responses in addition to humoral and Th cell responses [86, 122]. Influenza virosomes have been most extensively investigated. These virosomes contain influenza hemagglutinin, which binds to sialic acid residues on the cell surface and initiates receptor mediated endocytosis. Conformational changes in the influenza hemagglutinin due to acidification of the endosomes triggers the fusion of the endosomal membrane and the virosomal membrane, which enables release of the virosomal contents from the endosome into the cytosol. Subsequently the released antigens are degraded by the proteasome and presented through MHC I molecules [123]. Influenza virosomes have shown increased CTL responses against virosomal influenza [124-127], hepatitis C [128] and cancer antigens [129]. Virosomal influenza vaccines are the only virosomal vaccines that have been tested via the nasal route [130-133].

In addition to lipid based antigen delivery systems, polymeric biodegradable nanoparticles can enhance CTL induction *in vitro* [134] and *in vivo* after nasal vaccination

[135], as well as other routes [136-139]. Antigen loaded biodegradable PLGA nanoparticles are superior to nondegradable antigen adsorbed to latex nanoparticles [140], most likely due to hydrolysis of these polymeric nanoparticles in the acidic environment of endosomes. This facilitates endosomal escape [140-142] and antigen delivery into the cytosol, leading to enhanced MHC II presentation. The charge and structure of polymeric nanoparticles can also affect the uptake into DC. For instance, a positive charge has shown to increase phagocytic activity [141].

To summarize, vaccine delivery systems and endosomal escape mediators can be used for MHC II antigen presentation and thereby could increase CTL responses to an antigen.

Adjuvants

TLR ligands. CpG motifs in bacterial dsDNA are recognized by TLR 9. CpG oligodeoxynucleotides (ODN) have been tested in mice as adjuvant for nasal vaccines against several pathogens. Table III gives an overview of the results from studies in which TLR ligands have been tested as adjuvants for nasal vaccines. In general, the addition of CpG ODN to a nasal vaccine results in increased serum and mucosal antibody levels as well as increased cellular responses [143-145]. Generally, the addition of CpG ODN shifts the immune response from Th2 biased to a balanced Th1/Th2 response, i.e. it increases the production of Th1 cytokines and IgG2a.

Double stranded RNA and poly (I:C) are ligands for TLR 3. Poly (I:C) has been tested in mice as an adjuvant in a nasal influenza vaccine, resulting in protective immunity against influenza [146]. Poly (I:C) also increased humoral immune responses to two antigen formulations of *Bacillus anthracis*, inducing maturation and migration of DC and directing the immune response from mainly Th2 to a more balanced Th1/Th2 response. Moreover, sIgA was detected in broncho alveolar lavage fluid [147, 148].

TLR 3 and TLR 9 are located in endosomal membranes. Storni *et al* suggested therefore that TLR 3 and 9 ligands should be taken up by the same DC as the antigen to exert their adjuvant effect [149]. Following this hypothesis, Joseph *et al* encapsulated CpG motifs in liposomes with influenza antigen, which on nasal administration in mice led to an increased anti-influenza IgG2a response, cellular responses (splenocyte proliferation, CTL response and IFN- γ production), and protection against influenza virus challenge [150]. This is likely due to enhanced liposomal delivery of CpG motifs to the endosomal compartment.

LPS, a major component of the outer membrane of Gram-negative bacteria, is a ligand for TLR 2 and TLR 4, and its adjuvant potential has been tested in various studies. Both Th1 [151, 152] and Th2 responses [153-156] have been found after nasal administration of LPS-

containing vaccines. These contrary results are not yet fully understood. Iwasaki and Metzhitov suggested that a lower dose of administered LPS corresponds to environmental antigens and induces Th2 responses and allergic inflammation, whereas a high dose corresponds to responses against infection and induces Th1 responses [37]. Monophosphoryl lipid A, a derivative of LPS and ligand for TLR 4, has similar adjuvant effects as LPS in nasal vaccines [151]. Increased mucosal sIgA and serum antibodies were found by using monophosphoryl lipid A as an adjuvant [151, 157] when compared to LPS [151].

Bacterial flagellins are ligands for TLR 5 and have been tested in nasal vaccines [158-160]. They induce mucosal and serum humoral responses. *Vibrio vulnificus* derived flagellin has thus far been the only flagellin tested as an adjuvant and induced mainly Th2 responses against model antigen tetanus toxoid [158]. Further research should clarify the potential of this group of TLR ligands as adjuvants for nasal vaccines.

Other PRR include the intracellular NOD1 and NOD2 proteins, scavenger receptors, macrophage mannose receptors and other C-type lectin receptors as well as type 3 complement receptors [37]. For instance, targeting of the C-type lectin, mannose receptor, on DC significantly increased antigen presentation on MHC II molecules [161]; [38].

Altogether, it seems that many TLR ligands, and possibly other PRR ligands, can act as adjuvant for nasal vaccines. However, the shift towards Th1 immune responses as observed with parenteral vaccinations seems to be less evident with nasal vaccination where balanced Th1/Th2 immune responses are mostly observed with these adjuvants. Further research in the immunological mechanisms involved in eliciting mucosal immune responses is necessary to understand the role these adjuvants can play in future (nasal) vaccines.

Toxin-based adjuvants. Enterotoxins like CT and LT are strong mucosal adjuvants that induce mucosal as well as serum antibody responses [41, 42]. In 1997 the first commercial nasal virosomal influenza vaccine adjuvanted with LT became available. Although the vaccine yielded a high percentage of protection, it was withdrawn from the market because its use was associated with an increased risk of developing Bell's palsy [162]. The cause of the Bell's palsy was linked to LT [163] and consequently LT and CT have no longer been used intensively in humans as an adjuvant for nasal vaccines. It has been reported that the coadministration of CT or LT redirects the antigen into the olfactory neuroepithelium, likely the cause of the neurological toxicity [164]. In an effort to make safe adjuvants based on CT and LT, several mutants of the toxins have been developed and tested [165]. Amino acid mutations in the ADP-ribosyltransferase domain in the A subunit from CT and LT resulted in effective nontoxic mutants [166-173].

Nasal application of vaccines adjuvanted with CT and its nontoxic mutants induces Th2 type immune responses as well as mucosal sIgA production, whereas the differentiation of Th1 cells is suppressed [174-177]. On the other hand, LT and some mutants like LT(K63) [42, 178] induce a more balanced Th1/Th2 response [179, 180]. Some mutants of LT, like LT(R72) induce a specific Th2 response [42, 178], while other LT mutants like induce a more Th1 polarized response [181]. A clear correlation between mutation and type of induced immune response has not been established. A construct of CT with a synthetic dimer of the D-fragment of *Staphylococcus aureus* protein A, which targets to B-cell Ig receptors, resulted in a strong nontoxic adjuvant that induced a balanced Th1/Th2 response against several tested antigens [182].

Cytokines and costimulatory molecules. Cytokines like IL-1 [183, 184], IL-12 [185-187], and type 1 IFN [188, 189] have been used as adjuvants for nasal vaccines to induce stronger and regulated Th1/Th2 immune responses [165]. Especially IFN type 1 and IL-12 are promising nasal adjuvants promoting Th1 type immune responses. Costimulatory signals are non-antigen specific signals delivered by activated APC to T-cells or by Th cells to B-cells. Several pathways can be exploited as target for adjuvants. CD28, CD40, CD134 and CD137 have been investigated as adjuvant targets [190]. Monoclonal antibodies that mimic the agonistic binding of costimulatory molecules have been tested as ligands for these CD molecules. Anti-CD40 monoclonal antibodies were coadministered as an adjuvant with a liposomal formulation of an influenza CTL epitope in subcutaneous and i.n. vaccination in mice. A decrease of lung viral titers after non-lethal challenge was observed after i.n. but not after subcutaneous vaccination or nasal vaccination without anti-CD40 [191].

Table III. Examples of nasal vaccination studies using Toll like receptor ligands.

Ligand	TLR	Formulation	Pathogen	Response*				Reference
				Mucosal sigA	Serum Ab	CMI	Protection	
MALP-2	2-6	b-galactosidase with admixed MALP-2	none	Vaginal and bronchial IgA $\uparrow$	IgG $\uparrow$, IgG1 $\rightarrow$ IgG2a $\uparrow$	IL-10 $\uparrow$ (Th2), IL-2 (Th1) only detectable with MALP-2	Not applicable	(Rharbaoui et al. 2002; Rharbaoui et al. 2004)
Poly (I:C)	3	Poly (I:C) + recombinant protective antigen (rPA), or capsular poly- γ -d-glutamic acid (PGA)-BSA conjugate	Anthrax (<i>Bacillus anthracis</i>)	Brochial sigA $\uparrow$	Balanced IgG1/IgG2a, but shift to Th1	Expression of CD80 and CD86 and TNF- α secretion in DC	Anthrax lethal toxin neutralizing activity <i>in vitro</i>	(Sloat and Cui 2006a,b)
Poly (I:C)	3	Poly (I:C) + Ethyl ether split virus	Influenza A virus	Nasal sigA $\uparrow$	IgG $\uparrow$	Th1 and Th2 cytokines $\uparrow$ (IFN- α , β , γ , IL-4, IL-6 and IL-12p40)	Cross-protection against nasal challenge	(Ichinohe et al. 2005)
LPS	4	Invaplex (LPS + lpa proteins from <i>Shigella flexneri</i> 2a) admixed with OVA	none	Lung bronchial IgA $\uparrow$	IgG1 $\rightarrow$ (Th2), no α -OVA IgG2a	Proliferation of CLN and spleen cells, Th2 cytokines IL-4, IL-5 and IL-10 produced	Not applicable	(Kaminski et al. 2006)
LPS	2-4	Proteoliposomes from <i>Neisseria meningitidis</i> B, cochleate structure with incorporated ovalbumin or <i>Leishmania</i> antigens	<i>Leishmania</i> , <i>Neisseria meningitidis</i>	IgA in saliva $\uparrow$	α -PL IgG1 $\rightarrow$ IgG2a $\uparrow$	MHCII $\uparrow$ in DC, IFN γ production in spleen cells	Smaller lesions after leishmania major infection	(Perez et al. 2004)
LPS	2-4	Liposomal OpaB and OpaJ formulations with admixed LPS	<i>Neisseria meningitidis</i>	Nasal sigA $\uparrow$	IgG2b $\uparrow$ >IgG2a $\rightarrow$ (mixed Th1/Th2) LPS $\rightarrow$ Monophosphoryl lipid A	Not described	Bactericidal serum antibody titers	(de Jonge et al. 2004)
Monophosphoryl lipid A	4	Liposomal OpaB and OpaJ formulations with admixed LPS	<i>Neisseria meningitidis</i>	Nasal sigA $\uparrow$	IgG2b $\uparrow$ >IgG2a $\rightarrow$ (mixed Th1/Th2)	Not described	Bactericidal serum antibody titers	(de Jonge et al. 2004)
flagellin from <i>Vibrio vulnificus</i>	5	Tetanus toxoid with admixed flagellin	<i>Clostridium tetani</i>	Nasal sigA $\uparrow$	IgG1>IgG2a	Increased TLR 5 expression in lymph nodes and spleen	Yes	(Lee et al. 2006)
CpG ODN	9	non-toxic CRM197 conjugated Hib-PRP with admixed CpG ODN	<i>Haemophilus influenzae</i> type b	A-PRP and α -CRM197 IgA in saliva and BAL	A-PRP and α -CRM197 IgG2a $\uparrow$ and IgG3 $\uparrow$, shift to Th1	Not described	Not mentioned	(Mariotti et al. 2002)
CpG ODN	9	P6 outer membrane protein non-typable <i>Haemophilus influenzae</i> (NTHI) with admixed CpG ODN	Non-typable <i>Haemophilus influenzae</i>	sigA $\uparrow$ in nasal wash (similar to CT)	IgG1 $\rightarrow$, IgG2a $\uparrow$ balanced to Th1 (CT more IgG1)	IFN γ $\uparrow$ in CD 8 $\rightarrow$ T-cells, IL-6 $\uparrow$ and IFN γ $\uparrow$ in CD4 $\rightarrow$ T-cells	Increased clearance of NTHI nasal washes after challenge	(Abe et al. 2006; Kodama et al. 2006)
CpG ODN	9	Liposomal formulation of CpG ODN with admixed or co-encapsulated subunit vaccine	Influenza A virus	Nasal and bronchial IgA $\uparrow$, coencapsulated > admixed	IgG1 $\rightarrow$ and IgG2a $\uparrow$, more balanced IgG1/IgG2a than after i.m. (Th1)	IFN γ $\uparrow$ (Th1), Spleen proliferation $\uparrow$	Lung titers $\downarrow$, lowest in co-encapsulated formulation	(Joseph et al. 2002)
CpG ODN	9	Formaldehyde inactivated influenza virus with admixed CpG 1826 or <i>E. coli</i> DNA	Influenza A virus	sigA in saliva or vaginal washes $\leftrightarrow$	Abs $\uparrow$ at higher antigen dose, not significant for lower doses, <i>E. coli</i> DNA has stronger effect	Low proliferative responses from spleen of CLN isolated cells after <i>in vitro</i> restimulation	Not described	(Moldoveanu et al. 1998)
CpG ODN	9	Live Ankara virus vector with admixed CpG ODN	Vaccinia virus	Not described	No difference in virus neutralizing antibodies	CD8 $\rightarrow$ T cell response $\uparrow$, CpG can substitute for CD4 $\rightarrow$ help	Protective dosage $\downarrow$, mediated primarily by CD8 $\rightarrow$ in lungs	(Balyakov et al. 2006)
CpG ODN	9	Whole cell sonicate with admixed CpG ODN	<i>Helicobacter pylori</i>	Not detected	IgG and IgG1 no difference, IgG2a $\uparrow$ (Th1)	IFN γ -producing CD4 $\rightarrow$ and CD8 $\rightarrow$ T-cells	Protection associated with Th1 and IFN- γ	(Shi et al. 2005)
CpG ODN	9	Recombinant M type 8 with admixed CpG ODN	<i>Streptococcus pyogenes</i>	IgA $\uparrow$ in BAL	Total IgG $\uparrow$, IgG1 $\uparrow$, IgG2a $\uparrow$, IgG2b, Th1 type response CpG ODN< CT	Not described	Not described	(Teloni et al. 2004)
CpG ODN	9	Thelper-CTL epitope fusion peptides (pp65)	Cytomegalovirus	Not described	Not described	CTL stimulation $\uparrow$	Not described	(La Rosa et al. 2002)

Conclusions

Although research and development of nasal vaccines has gained momentum over the last years, only one nasal vaccine is currently approved for human use, indicating that advances towards new effective vaccines have been slow, in particular for inactivated/subunit vaccines. However, the various attempts that have failed can teach us not to bet on one single horse. The opportunities in nasal vaccination are not in a single research field, but require the integration of immunology, biotechnology, microbiology and pharmaceutical sciences. Mechanistic insight into the hurdles that limit the efficacy of nasal vaccination will create opportunities for rationally designed nasal vaccines that can overcome these barriers. A concerted approach, combining various targeting techniques discussed in this paper, includes the use of particulate antigen carriers, which can be furnished with distinct functionalities such as mucoadhesive polymers, M-cell or DC targeting ligands, adjuvants and endosomal escape promoters. This could lead to “tailor made” vaccines that provide similar or even superior protection to diseases as provided by classical parental vaccines. The biggest challenge will be to combine these techniques in such a way that they do not interfere with one another, but synergistically enhance vaccine efficacy.

Acknowledgments

The authors thank Elly van Riet for critically reading the manuscript and her helpful suggestions, and Martijn Pieck for making the illustrations.

References

1. Rumke, H.C. and H.K. Visser, *[Childhood vaccinations anno 2004. I. Effectiveness and acceptance of the Dutch National Vaccination Programme]* Ned Tijdschr Geneesk, 2004. **148**(8): p. 356-63.
2. Crockett, M. and J. Keystone, "I hate needles" and other factors impacting on travel vaccine uptake J Travel Med, 2005. **12 Suppl 1**: p. S41-6.
3. Bitsori, M., et al., *Vaccination coverage among adolescents in certain provinces of Greece* Acta Paediatr, 2005. **94**(8): p. 1122-5.
4. Kalies, H., et al., *Immunisation status of children in Germany: temporal trends and regional differences* Eur J Pediatr, 2006. **165**(1): p. 30-6.
5. Szucs, T.D. and D. Muller, *Influenza vaccination coverage rates in five European countries-a population-based cross-sectional analysis of two consecutive influenza seasons* Vaccine, 2005. **23**(43): p. 5055-63.
6. Hak, E., et al., *Negative attitude of highly educated parents and health care workers towards future vaccinations in the Dutch childhood vaccination program* Vaccine, 2005. **23**(24): p. 3103-7.
7. *President Requests 2.6 Percent NIH Budget Increase in 2005* 2005; Available from: http://www.nih.gov/news/NIH-Record/03_02_2004/story03.htm.
8. Enserink, M. *Radical Steps Urged to Help Underserved* 2000; Available from: <http://www.sciencemag.org/cgi/content/full/288/5471/1563a?ck=nck>.
9. Harrington, M. *To Double, or Not to Double? Bioterror Buys a Budget Boost* 2002; Available from: <http://www.aidsinfonyc.org/tag/activism/bioterror.html>.
10. Brandtzaeg, P., *History of oral tolerance and mucosal immunity* Ann N Y Acad Sci, 1996. **778**: p. 1-27.
11. Kyd, J.M., A.R. Foxwell, and A.W. Cripps, *Mucosal immunity in the lung and upper airway* Vaccine, 2001. **19**(17-19): p. 2527-33.
12. Neutra, M.R., A. Frey, and J.P. Kraehenbuhl, *Epithelial M cells: gateways for mucosal infection and immunization* Cell, 1996. **86**(3): p. 345-8.
13. van der Ven, I. and T. Sminia, *The development and structure of mouse nasal-associated lymphoid tissue: an immuno- and enzyme-histochemical study* Reg Immunol, 1993. **5**(2): p. 69-75.
14. Jeong, K.I., et al., *Ultrastructural study on the follicle-associated epithelium of nasal-associated lymphoid tissue in specific pathogen-free (SPF) and conventional environment-adapted (SPF-CV) rats* J Anat, 2000. **196 (Pt 3)**: p. 443-51.
15. Morag, A., et al., *In vitro correlates of cell-mediated immunity in human tonsils after natural or induced Rubella virus infection* J Infect Dis, 1975. **131**(4): p. 409-16.
16. Ogra, P.L., *Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus* N Engl J Med, 1971. **284**(2): p. 59-64.
17. Zuercher, A.W., et al., *Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses* J Immunol, 2002. **168**(4): p. 1796-803.
18. Shimoda, M., et al., *Isotype-specific selection of high affinity memory B cells in nasal-associated lymphoid tissue* J Exp Med, 2001. **194**(11): p. 1597-607.
19. Giudice, E.L. and J.D. Campbell, *Needle-free vaccine delivery* Adv Drug Deliv Rev, 2006. **58**(1): p. 68-89.
20. *Diseases, I.f.V.R.N.V.a.l., New Vaccines against Infectious Diseases: Research and Development Status* 2005.
21. Neutra, M.R., E. Pringault, and J.P. Kraehenbuhl, *Antigen sampling across epithelial barriers and induction of mucosal immune responses* Annu Rev Immunol, 1996. **14**: p. 275-300.

22. Watson, C.J., M. Rowland, and G. Warhurst, *Functional modeling of tight junctions in intestinal cell monolayers using polyethylene glycol oligomers* Am J Physiol Cell Physiol, 2001. **281**(2): p. C388-97.
23. Illum, L., *Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems?* J Pharm Sci, 2007. **96**(3): p. 473-83.
24. Fujimura, Y., et al., *The role of M cells of human nasopharyngeal lymphoid tissue in influenza virus sampling*. Virchows Arch, 2004. **444**(1): p. 36-42.
25. Fujimura, Y., *Evidence of M cells as portals of entry for antigens in the nasopharyngeal lymphoid tissue of humans* Virchows Arch, 2000. **436**(6): p. 560-6.
26. Park, H.S., et al., *Membranous cells in nasal-associated lymphoid tissue: a portal of entry for the respiratory mucosal pathogen group A streptococcus* J Immunol, 2003. **171**(5): p. 2532-7.
27. Gebert, A., *Identification of M-cells in the rabbit tonsil by vimentin immunohistochemistry and in vivo protein transport* Histochem Cell Biol, 1995. **104**(3): p. 211-20.
28. Gebert, A., B. Willfuhr, and R. Pabst, *The rabbit M-cell marker vimentin is present in epithelial cells of the tonsil crypt* Acta Otolaryngol, 1995. **115**(5): p. 697-700.
29. Styers, M.L., A.P. Kowalczyk, and V. Faundez, *Intermediate filaments and vesicular membrane traffic: the odd couple's first dance?* Traffic, 2005. **6**(5): p. 359-65.
30. Brooking, J., S.S. Davis, and L. Illum, *Transport of nanoparticles across the rat nasal mucosa*. J Drug Target, 2001. **9**(4): p. 267-79.
31. Illum, L., *Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems?* J Pharm Sci, 2006.
32. Cervi, L., et al., *Cutting edge: dendritic cells copulsed with microbial and helminth antigens undergo modified maturation, segregate the antigens to distinct intracellular compartments, and concurrently induce microbe-specific Th1 and helminth-specific Th2 responses*. J Immunol, 2004. **172**(4): p. 2016-20.
33. Ackerman, A.L. and P. Cresswell, *Cellular mechanisms governing cross-presentation of exogenous antigens*. Nat Immunol, 2004. **5**(7): p. 678-84.
34. Ackerman, A.L., et al., *Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells*. Nat Immunol, 2005. **6**(1): p. 107-13.
35. Burgdorf, S., et al., *Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation*. Science, 2007. **316**(5824): p. 612-6.
36. Blander, J.M. and R. Medzhitov, *On regulation of phagosome maturation and antigen presentation*. Nat Immunol, 2006. **7**(10): p. 1029-35.
37. Iwasaki, A. and R. Medzhitov, *Toll-like receptor control of the adaptive immune responses*. Nat Immunol, 2004. **5**(10): p. 987-95.
38. Pashine, A., N.M. Valiante, and J.B. Ulmer, *Targeting the innate immune response with improved vaccine adjuvants*. Nat Med, 2005. **11**(4 Suppl): p. S63-8.
39. Akira, S. and K. Takeda, *Toll-like receptor signalling*. Nat Rev Immunol, 2004. **4**(7): p. 499-511.
40. Wang, Q., et al., *A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2*. J Exp Med, 2006. **203**(13): p. 2853-63.
41. Imaoka, K., et al., *Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues*. J Immunol, 1998. **161**(11): p. 5952-8.

42. Ryan, E.J., et al., *Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity*. J Immunol, 2000. **165**(10): p. 5750-9.
43. Arce, S., et al., *Differential binding of Escherichia coli enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation, and activation of lymphoid cells*. Infect Immun, 2005. **73**(5): p. 2718-27.
44. Yamamoto, M., et al., *Genetically manipulated bacterial toxin as a new generation mucosal adjuvant* Scand J Immunol, 2001. **53**(3): p. 211-7.
45. Schijns, V.E., *Immunological concepts of vaccine adjuvant activity*. Curr Opin Immunol, 2000. **12**(4): p. 456-63.
46. Smart, J.D., *The basics and underlying mechanisms of mucoadhesion*. Adv Drug Deliv Rev, 2005. **57**(11): p. 1556-68.
47. Bogataj, M., et al., *The correlation between zeta potential and mucoadhesion strength on pig vesical mucosa*. Biol Pharm Bull, 2003. **26**(5): p. 743-6.
48. Ugwoke, M.I., et al., *Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives*. Adv Drug Deliv Rev, 2005. **57**(11): p. 1640-65.
49. Dodane, V., M. Amin Khan, and J.R. Merwin, *Effect of chitosan on epithelial permeability and structure* Int J Pharm, 1999. **182**(1): p. 21-32.
50. Bernkop-Schnurch, A., C.E. Kast, and M.F. Richter, *Improvement in the mucoadhesive properties of alginate by the covalent attachment of cysteine* J Control Release, 2001. **71**(3): p. 277-85.
51. Grabovac, V., D. Guggi, and A. Bernkop-Schnurch, *Comparison of the mucoadhesive properties of various polymers*. Adv Drug Deliv Rev, 2005. **57**(11): p. 1713-23.
52. Singh, M., M. Briones, and D.T. O'Hagan, *A novel bioadhesive intranasal delivery system for inactivated influenza vaccines* J Control Release, 2001. **70**(3): p. 267-76.
53. Jabbal-Gill, I., et al., *Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice*. Vaccine, 1998. **16**(20): p. 2039-46.
54. Hilfenhaus, J., et al., *Herpes simplex virus subunit vaccine: characterization of the virus strain used and testing of the vaccine* Dev Biol Stand, 1982. **52**: p. 321-31.
55. Jabbal-Gill, I., et al., *Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice* Vaccine, 1998. **16**(20): p. 2039-46.
56. McNeela, E.A., et al., *A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery* Vaccine, 2000. **19**(9-10): p. 1188-98.
57. Coeshott, C.M., et al., *Pluronic F127-based systemic vaccine delivery systems* Vaccine, 2004. **22**(19): p. 2396-405.
58. Read, R.C., et al., *Effective nasal influenza vaccine delivery using chitosan*. Vaccine, 2005. **23**(35): p. 4367-74.
59. Gogev, S., et al., *Glycol chitosan improves the efficacy of intranasally administrated replication defective human adenovirus type 5 expressing glycoprotein D of bovine herpesvirus 1* Vaccine, 2004. **22**(15-16): p. 1946-53.

60. Soane, R.J., et al., *Clearance characteristics of chitosan based formulations in the sheep nasal cavity* Int J Pharm, 2001. **217**(1-2): p. 183-91.
61. Koping-Hoggard, M., A. Sanchez, and M.J. Alonso, *Nanoparticles as carriers for nasal vaccine delivery* Expert Rev Vaccines, 2005. **4**(2): p. 185-96.
62. Shephard, M.J., et al., *Immunogenicity of bovine parainfluenza type 3 virus proteins encapsulated in nanoparticle vaccines, following intranasal administration to mice* Res Vet Sci, 2003. **74**(2): p. 187-90.
63. Feng, L., et al., *Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres* J Control Release, 2006. **112**(1): p. 35-42.
64. Kang, M.L., et al., *In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT* Eur J Pharm Biopharm, 2006. **63**(2): p. 215-20.
65. Moore, A., et al., *Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8⁺ cytotoxic T lymphocytes and CD4⁺ Th1 cells* Vaccine, 1995. **13**(18): p. 1741-9.
66. Higaki, M., et al., *Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin*. Vaccine, 1998. **16**(7): p. 741-5.
67. Brooking, J., S.S. Davis, and L. Illum, *Transport of nanoparticles across the rat nasal mucosa* J Drug Target, 2001. **9**(4): p. 267-79.
68. de Haan, A., et al., *Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice* Vaccine, 1995. **13**(14): p. 1320-4.
69. Baca-Estrada, M.E., et al., *Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses* Vaccine, 2000. **18**(21): p. 2203-11.
70. Joseph, A., et al., *A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice*. Vaccine, 2006. **24**(18): p. 3990-4006.
71. Nagamoto, T., et al., *Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery* Pharm Res, 2004. **21**(4): p. 671-4.
72. Amidi, M., et al., *N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model* Vaccine, 2007. **25**(1): p. 144-53.
73. Jaganathan, K.S. and S.P. Vyas, *Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally* Vaccine, 2006. **24**(19): p. 4201-11.
74. Vila, A., et al., *Design of biodegradable particles for protein delivery* J Control Release, 2002. **78**(1-3): p. 15-24.
75. Shakweh, M., et al., *Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice* Eur J Pharm Biopharm, 2005. **61**(1-2): p. 1-13.
76. Matsunaga, Y., et al., *Oral immunization with size-purified microsphere beads as a vehicle selectively induces systemic tolerance and sensitization* Vaccine, 2000. **19**(4-5): p. 579-88.
77. Xiang, S.D., et al., *Pathogen recognition and development of particulate vaccines: does size matter? . Methods*, 2006. **40**(1): p. 1-9.

78. Vila, A., et al., *PLA-PEG particles as nasal protein carriers: the influence of the particle size* Int J Pharm, 2005. **292**(1-2): p. 43-52.
79. Jung, T., et al., *Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice* Pharm Res, 2001. **18**(3): p. 352-60.
80. Sandri, G., et al., *Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro (Caco-2 cells) and ex vivo (excised rat jejunum) models* Eur J Pharm Biopharm, 2007. **65**(1): p. 68-77.
81. Fujimura, Y., et al., *Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue* Med Mol Morphol, 2006. **39**(4): p. 181-6.
82. Baca-Estrada, M.E., M. Foldvari, and M. Snider, *Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12* J Interferon Cytokine Res, 1999. **19**(5): p. 455-62.
83. Tafaghodi, M., S.A. Sajadi Tabassi, and M.R. Jaafari, *Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN* Int J Pharm, 2006. **319**(1-2): p. 37-43.
84. Oliveira, M.L., et al., *Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A* Microbes Infect, 2006. **8**(4): p. 1016-24.
85. Audouy, S.A., et al., *Development of lactococcal GEM-based pneumococcal vaccines* Vaccine, 2006.
86. Huckriede, A., et al., *The virosome concept for influenza vaccines*. Vaccine, 2005. **23 Suppl 1**: p. S26-38.
87. Bron, R., A. Ortiz, and J. Wilschut, *Cellular cytoplasmic delivery of a polypeptide toxin by reconstituted influenza virus envelopes (virosomes)* Biochemistry, 1994. **33**(31): p. 9110-7.
88. Cusi, M.G., *Applications of influenza virosomes as a delivery system*. Hum Vaccin, 2006. **2**(1): p. 1-7.
89. Cusi, M.G., et al., *Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity*. Vaccine, 2002. **20**(29-30): p. 3436-42.
90. Cusi, M.G., *The response to plasmid DNA-virosome vaccination: a role for circulating antibodies?* Trends Immunol, 2001. **22**(7): p. 355.
91. Owen, R.L. and D.K. Bhalla, *Cytochemical analysis of alkaline phosphatase and esterase activities and of lectin-binding and anionic sites in rat and mouse Peyer's patch M cells* Am J Anat, 1983. **168**(2): p. 199-212.
92. Hultgren, S.J., et al., *Pilus and nonpilus bacterial adhesins: assembly and function in cell recognition* Cell, 1993. **73**(5): p. 887-901.
93. Sharma, R., et al., *Lectin binding reveals divergent carbohydrate expression in human and mouse Peyer's patches* Histochem Cell Biol, 1996. **105**(6): p. 459-65.
94. Clark, M.A., M.A. Jepson, and B.H. Hirst, *Lectin binding defines and differentiates M-cells in mouse small intestine and caecum* Histochem Cell Biol, 1995. **104**(2): p. 161-8.
95. Lee, Y.S., *Lectin reactivity in human large bowel* Pathology, 1987. **19**(4): p. 397-401.
96. Foster, N., et al., *Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo* Vaccine, 1998. **16**(5): p. 536-41.
97. Carreno-Gomez, B., J.F. Woodley, and A.T. Florence, *Studies on the uptake of tomato lectin nanoparticles in everted gut sacs* Int J Pharm, 1999. **183**(1): p. 7-11.
98. Hussain, N., P.U. Jani, and A.T. Florence, *Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat* Pharm Res, 1997. **14**(5): p. 613-8.

99. Russell-Jones, G.J., H. Veitch, and L. Arthur, *Lectin-mediated transport of nanoparticles across Caco-2 and OK cells* Int J Pharm, 1999. **190**(2): p. 165-74.
100. Takata, S., O. Ohtani, and Y. Watanabe, *Lectin binding patterns in rat nasal-associated lymphoid tissue (NALT) and the influence of various types of lectin on particle uptake in NALT* Arch Histol Cytol, 2000. **63**(4): p. 305-12.
101. Wang, X., et al., *Transgene vaccination using Ulex europaeus agglutinin I (UEA-1) for targeted mucosal immunization against HIV-1 envelope*. Vaccine, 2005. **23**(29): p. 3836-42.
102. Giannasca, P.J., J.A. Boden, and T.P. Monath, *Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins* Infect Immun, 1997. **65**(10): p. 4288-98.
103. Rogers, G.N. and J.C. Paulson, *Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin* Virology, 1983. **127**(2): p. 361-73.
104. Tong, H.H., et al., *Effect of neuraminidase on receptor-mediated adherence of Streptococcus pneumoniae to chinchilla tracheal epithelium* Acta Otolaryngol, 2002. **122**(4): p. 413-9.
105. Corthesy, B., *Roundtrip ticket for secretory IgA: role in mucosal homeostasis?* J Immunol, 2007. **178**(1): p. 27-32.
106. Favre, L., F. Spertini, and B. Corthesy, *Secretory IgA possesses intrinsic modulatory properties stimulating mucosal and systemic immune responses*. J Immunol, 2005. **175**(5): p. 2793-800.
107. Tiwari, B., et al., *Immunoglobulin immobilized liposomal constructs for transmucosal vaccination through nasal route*. J Liposome Res, 2010.
108. Tyrer, P., et al., *Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacterium* Infect Immun, 2006. **74**(1): p. 625-31.
109. Clark, M.A., B.H. Hirst, and M.A. Jepson, *M-cell surface beta1 integrin expression and invasin-mediated targeting of Yersinia pseudotuberculosis to mouse Peyer's patch M cells* Infect Immun, 1998. **66**(3): p. 1237-43.
110. Frankel, G., et al., *The cell-binding domain of intimin from enteropathogenic Escherichia coli binds to beta1 integrins* J Biol Chem, 1996. **271**(34): p. 20359-64.
111. Cruz, N., et al., *Role of mucin, mannose, and beta-1 integrin receptors in Escherichia coli translocation across Caco-2 cell monolayers* Shock, 1994. **2**(2): p. 121-6.
112. Gullberg, E., et al., *Identification of cell adhesion molecules in the human follicle-associated epithelium that improve nanoparticle uptake into the Peyer's patches*. J Pharmacol Exp Ther, 2006. **319**(2): p. 632-9.
113. Hicks, W., Jr., et al., *Isolation and characterization of basal cells from human upper respiratory epithelium* Exp Cell Res, 1997. **237**(2): p. 357-63.
114. Foged, C., A. Sundblad, and L. Hovgaard, *Targeting vaccines to dendritic cells*. Pharm Res, 2002. **19**(3): p. 229-38.
115. Rock, K.L. and K. Clark, *Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway*. J Immunol, 1996. **156**(10): p. 3721-6.
116. Harding, C.V. and R. Song, *Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules*. J Immunol, 1994. **153**(11): p. 4925-33.
117. Lenarczyk, A., et al., *ISCOM based vaccines for cancer immunotherapy*. Vaccine, 2004. **22**(8): p. 963-74.

118. Malliaros, J., et al., *Association of antigens to ISCOMATRIX adjuvant using metal chelation leads to improved CTL responses*. Vaccine, 2004. **22**(29-30): p. 3968-75.
119. Stewart, T.J., et al., *ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines*, in Vaccine. 2004. p. 3738-43.
120. Pearce, M.J. and D. Drane, *ISCOMATRIX adjuvant for antigen delivery*. Adv Drug Deliv Rev, 2005. **57**(3): p. 465-74.
121. Sanders, M.T., et al., *ISCOM-based vaccines: the second decade*. Immunol Cell Biol, 2005. **83**(2): p. 119-28.
122. Daemen, T., et al., *Virosomes for antigen and DNA delivery*. Adv Drug Deliv Rev, 2005. **57**(3): p. 451-63.
123. Bungener, L., et al., *Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity*. Vaccine, 2005. **23**(10): p. 1232-41.
124. Huckriede, A., et al., *Influenza virosomes in vaccine development*. Methods Enzymol, 2003. **373**: p. 74-91.
125. Lambkin, R., et al., *Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine*. Vaccine, 2004. **22**(31-32): p. 4390-6.
126. Durrer, P., et al., *Mucosal antibody response induced with a nasal virosome-based influenza vaccine*. Vaccine, 2003. **21**(27-30): p. 4328-34.
127. Schumacher, R., et al., *Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation*. Vaccine, 2004. **22**(5-6): p. 714-23.
128. Amacker, M., et al., *Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells*. Int Immunol, 2005. **17**(6): p. 695-704.
129. Schwaninger, R., et al., *Virosomes as new carrier system for cancer vaccines*. Cancer Immunol Immunother, 2004. **53**(11): p. 1005-17.
130. Glueck, R., *Review of intranasal influenza vaccine*. Adv Drug Deliv Rev, 2001. **51**(1-3): p. 203-11.
131. Gluck, U., J.O. Gebbers, and R. Gluck, *Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers*. J Virol, 1999. **73**(9): p. 7780-6.
132. de, B., et al., *An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults*. Clin Ther, 2002. **24**(1): p. 100-11.
133. Cusi, M.G., et al., *Immunopotentiating of mucosal and systemic antibody responses in mice by intranasal immunization with HLT-combined influenza virosomal vaccine*. Vaccine, 2000. **18**(25): p. 2838-42.
134. Kwon, Y.J., et al., *Directed antigen presentation using polymeric microparticulate carriers degradable at lysosomal pH for controlled immune responses*. Mol Pharm, 2005. **2**(1): p. 83-91.
135. Partidos, C.D., P. Vohra, and M.W. Steward, *Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides*. Immunology, 1996. **87**(2): p. 179-85.
136. Partidos, C.D., et al., *CTL responses induced by a single immunization with peptide encapsulated in biodegradable microparticles*. J Immunol Methods, 1997. **206**(1-2): p. 143-51.
137. Partidos, C.D., et al., *Induction of cytotoxic T-cell responses following oral immunization with synthetic peptides encapsulated in PLG microparticles*. J Control Release, 1999. **62**(3): p. 325-32.
138. Partidos, C.D., et al., *Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes*. Mol Immunol, 1996. **33**(6): p. 485-91.
139. Nixon, D.F., et al., *Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity*. Vaccine, 1996. **14**(16): p. 1523-30.

140. Shen, H., et al., *Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles*. Immunology, 2006. **117**(1): p. 78-88.
141. Kwon, Y.J., et al., *Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles*. J Control Release, 2005. **105**(3): p. 199-212.
142. Kwon, Y.J., et al., *In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles*. Proc Natl Acad Sci U S A, 2005. **102**(51): p. 18264-8.
143. Abe, N., et al., *Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx* Laryngoscope, 2006. **116**(3): p. 407-12.
144. Kodama, S., et al., *Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant* Laryngoscope, 2006. **116**(2): p. 331-5.
145. Joseph, A., et al., *Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines* Vaccine, 2002. **20**(27-28): p. 3342-54.
146. Ichinohe, T., et al., *Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection*. J Virol, 2005. **79**(5): p. 2910-9.
147. Sloat, B.R. and Z. Cui, *Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli*. Vaccine, 2006. **24**(40-41): p. 6405-13.
148. Sloat, B.R. and Z. Cui, *Nasal immunization with anthrax protective antigen protein adjuvanted with polyribonucleosinic-polyribocytidylic acid induced strong mucosal and systemic immunities*. Pharm Res, 2006. **23**(6): p. 1217-26.
149. Storni, T., et al., *Immunity in response to particulate antigen-delivery systems*. Adv Drug Deliv Rev, 2005. **57**(3): p. 333-55.
150. Joseph, A., et al., *Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines*. Vaccine, 2002. **20**(27-28): p. 3342-54.
151. de Jonge, M.I., et al., *Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins*. Vaccine, 2004. **22**(29-30): p. 4021-8.
152. Perez, O., et al., *Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern*. Immunol Cell Biol, 2004. **82**(6): p. 603-10.
153. Redecke, V., et al., *Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma*. J Immunol, 2004. **172**(5): p. 2739-43.
154. Pulendran, B., et al., *Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo*. J Immunol, 2001. **167**(9): p. 5067-76.
155. Agrawal, S., et al., *Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos*. J Immunol, 2003. **171**(10): p. 4984-9.
156. Kaminski, R.W., K.R. Turbyfill, and E.V. Oaks, *Mucosal adjuvant properties of the Shigella invasin complex*. Infect Immun, 2006. **74**(5): p. 2856-66.
157. Childers, et al., *Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen*. Infect Immun, 2000. **68**(10): p. 5509-16.
158. Lee, S.E., et al., *A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity*. Infect Immun, 2006. **74**(1): p. 694-702.
159. Strindeli, L., M. Filler, and I. Sjöholm, *Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice*. Vaccine, 2004. **22**(27-28): p. 3797-808.

160. Sbrogio-Almeida, M.E. and L.C. Ferreira, *Flagellin expressed by live Salmonella vaccine strains induces distinct antibody responses following delivery via systemic or mucosal immunization routes*. FEMS Immunol Med Microbiol, 2001. **30**(3): p. 203-8.
161. Lanzavecchia, A., *Mechanisms of antigen uptake for presentation* Curr Opin Immunol, 1996. **8**(3): p. 348-54.
162. Mutsch, M., et al., *Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland*. N Engl J Med, 2004. **350**(9): p. 896-903.
163. Couch, R.B., *Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy*. N Engl J Med, 2004. **350**(9): p. 860-1.
164. van Ginkel, F.W., et al., *Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract*. Infect Immun, 2005. **73**(10): p. 6892-902.
165. Yuki, Y. and H. Kiyono, *New generation of mucosal adjuvants for the induction of protective immunity*. Rev Med Virol, 2003. **13**(5): p. 293-310.
166. Douce, G., et al., *Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli*. Vaccine, 1998. **16**(11-12): p. 1065-73.
167. Takahashi, H., et al., *Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus calmette-guerin in mice*. Vaccine, 2006. **24**(17): p. 3591-8.
168. Kende, M., et al., *Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant*. Vaccine, 2006. **24**(12): p. 2213-21.
169. Bowe, F., et al., *Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin*. Infect Immun, 2004. **72**(7): p. 4052-60.
170. Yamamoto, M., et al., *A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A*. J Immunol, 1998. **161**(8): p. 4115-21.
171. Yamamoto, M., et al., *Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant*. J Immunol, 1999. **162**(12): p. 7015-21.
172. Yamamoto, S., et al., *A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity*. Proc Natl Acad Sci U S A, 1997. **94**(10): p. 5267-72.
173. Pine, S., et al., *Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli*. J Control Release, 2002. **85**(1-3): p. 263-70.
174. Ohmura, M., et al., *Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin*. Vaccine, 2001. **20**(5-6): p. 756-62.
175. Periwal, S.B., et al., *A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine*. Vaccine, 2003. **21**(5-6): p. 376-85.
176. Yamamoto, M., et al., *Genetically manipulated bacterial toxin as a new generation mucosal adjuvant*. Scand J Immunol, 2001. **53**(3): p. 211-7.
177. Braun, M.C., et al., *Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression*. J Exp Med, 1999. **189**(3): p. 541-52.
178. Ryan, E.J., et al., *Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells*. Infect Immun, 1999. **67**(12): p. 6270-80.

179. Takahashi, I., et al., *Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin*. J Infect Dis, 1996. **173**(3): p. 627-35.
180. Yamamoto, M., et al., *Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses*. J Infect Dis, 2000. **182**(1): p. 180-90.
181. Takahashi, H., et al., *Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus calmette-guerin in mice* Vaccine, 2006. **24**(17): p. 3591-8.
182. Lycke, N., *Targeted vaccine adjuvants based on modified cholera toxin*. Curr Mol Med, 2005. **5**(6): p. 591-7.
183. Egan, M.A., et al., *A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques*. Vaccine, 2004. **22**(27-28): p. 3774-88.
184. Staats, H.F. and F.A. Ennis, Jr., *IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens*. J Immunol, 1999. **162**(10): p. 6141-7.
185. Boyaka, P.N., et al., *IL-12 is an effective adjuvant for induction of mucosal immunity*. J Immunol, 1999. **162**(1): p. 122-8.
186. Marinaro, M., et al., *Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin*. J Immunol, 1999. **162**(1): p. 114-21.
187. Boyaka, P.N., J.W. Lillard, Jr., and J. McGhee, *Interleukin 12 and innate molecules for enhanced mucosal immunity*. Immunol Res, 1999. **20**(3): p. 207-17.
188. Bracci, L., et al., *Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level*. Vaccine, 2005. **23**(23): p. 2994-3004.
189. Proietti, E., et al., *Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model*. J Immunol, 2002. **169**(1): p. 375-83.
190. Barr, T.A., J. Carling, and A.W. Heath, *Co-stimulatory agonists as immunological adjuvants*. Vaccine, 2006. **24**(17): p. 3399-407.
191. Ninomiya, A., et al., *Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice*. Vaccine, 2002. **20**(25-26): p. 3123-9.